Adalimumab

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Juvenile Idiopathic Arthritis

Conditions

Juvenile Idiopathic Arthritis

Trial Timeline

Mar 1, 2009 → Mar 1, 2013

NCT ID

NCT00775437

About Adalimumab

Adalimumab is a phase 3 stage product being developed by AbbVie for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00775437. Target conditions include Juvenile Idiopathic Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis were approved

Approved (0) Terminated (2) Active (18)

🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄AdalimumabEisaiPhase 3

🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05414201	Approved	Completed	Jul 7, 2022	Jun 10, 2024	Non-infectious Intermediate Posterior- or Pan-uveitis
NCT04183608	Approved	Recruiting	Jan 14, 2020	May 1, 2028	Ulcerative Colitis
NCT03311464	Phase 3	Completed	Oct 27, 2017	Apr 21, 2020	Pyoderma Gangrenosum
NCT03261102	Pre-clinical	Active	Jan 17, 2017	Jun 1, 2025	Crohn Disease
NCT02897115	Approved	Terminated	Sep 12, 2016	Dec 21, 2017	Axial Spondyloarthritis
NCT02904902	Phase 3	Completed	Sep 6, 2016	May 30, 2019	Hidradenitis Suppurativa
NCT02668640	Pre-clinical	Completed	May 1, 2016	Aug 13, 2018	Rheumatoid Arthritis
NCT02750800	Pre-clinical	Completed	Apr 7, 2016	Apr 3, 2018	Rheumatoid Arthritis
NCT02739828	Pre-clinical	Completed	Apr 7, 2016	Mar 28, 2018	Hidradenitis Suppurativa
NCT02634541	Approved	UNKNOWN	Jan 1, 2016	Dec 1, 2017	Ankylosing Spondyloarthritis
NCT02632175	Phase 3	Completed	Nov 26, 2015	Apr 8, 2025	Ulcerative Colitis
NCT02533375	Phase 3	Completed	Sep 28, 2015	Jul 20, 2017	Generalized Pustular Psoriasis (GPP)
NCT02499783	Phase 3	Completed	Aug 17, 2015	Dec 15, 2017	Crohn's Disease
NCT02198651	Approved	Completed	Jan 5, 2015	Aug 8, 2018	Rheumatoid Arthritis
NCT02333383	Pre-clinical	Completed	Dec 31, 2014	Aug 8, 2017	Ankylosing Spondylitis
NCT02539849	Pre-clinical	Completed	Dec 1, 2014	Dec 19, 2017	Crohn Disease
NCT02185014	Phase 3	Completed	Aug 12, 2014	Nov 3, 2017	Crohn's Disease
NCT02148718	Approved	Completed	Jun 1, 2014	Jan 1, 2017	Moderate to Severe Crohn's Disease
NCT02065622	Phase 3	Completed	Mar 27, 2014	Nov 11, 2019	Ulcerative Colitis (UC)
NCT02016482	Phase 3	Completed	Jan 1, 2014	Apr 1, 2016	Nail Psoriasis

Competing Products

20 competing products in Juvenile Idiopathic Arthritis

See all competitors

Product	Company	Stage	Hype Score
PLX-200 + Placebo	Polaryx Therapeutics	Phase 3	37
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
Adalimumab	Eisai	Phase 3	40
Abatacept	Ono Pharmaceutical	Phase 3	40
Ixekizumab + Adalimumab	Eli Lilly	Phase 3	44
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Phase 3	47
Baricitinib + Tocilizumab	Eli Lilly	Phase 3	47
adalimumab + Methotrexate	AbbVie	Pre-clinical	26
Upadacitinib	AbbVie	Phase 1	33
Upadacitinib + Tocilizumab	AbbVie	Phase 3	47
Adalimumab + Risankizumab	AbbVie	Phase 3	47
naproxen + esomeprazole	AstraZeneca	Phase 1	29
Alendronate (Fosamax)	Merck	Pre-clinical	26
canakinumab	Novartis	Phase 3	40
Secukinumab	Novartis	Phase 1	36
ACZ885 150 mg (Canakinumab)	Novartis	Phase 3	40